Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritis

Arata Nakajima,Keiichiro Terayama,Masato Sonobe,Yasuchika Aoki,Hiroshi Takahashi,Yorikazu Akatsu,Junya Saito,Shinji Taniguchi,Manabu Yamada,Ayako Kubota,Koichi Nakagawa

Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritis

2019

Arata Nakajima
Keiichiro Terayama
Masato Sonobe
Yasuchika Aoki
Hiroshi Takahashi
Yorikazu Akatsu
Junya Saito
Shinji Taniguchi
Manabu Yamada
Ayako Kubota
Koichi Nakagawa

Background To verify whether serum levels of reactive oxygen metabolites (ROM) are predictive of future clinical remission in patients with rheumatoid arthritis (RA) receiving tocilizumab (TCZ) therapy.

Keywords:

Gastroenterology
Tocilizumab therapy
Tocilizumab
Rheumatology
Biomarker (medicine)
Medicine
Internal medicine
Rheumatoid arthritis
Disease
Odds ratio
Area under the curve
Confidence interval
Receiver operating characteristic

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations